Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care

A global medical effort has officially changed the name of a widespread women’s health condition from Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The announcement, made on May 12, 2026, aims to improve the diagnosis and care of a condition that affects more than 170 million women worldwide, or approximately 1 in 8 women.

The name change is intended to address long-standing misunderstandings regarding the nature of the disorder. For years, the term polycystic led many to believe the condition was primarily about ovarian cysts, which medical experts say contributed to inadequate treatment and missed diagnoses.

Correcting a Clinical Misunderstanding

The transition to Polyendocrine Metabolic Ovarian Syndrome reflects a deeper understanding of the condition as a complex, long-term endocrine disorder rather than a localized ovarian issue. Experts now emphasize that the condition is characterized by hormone fluctuations that impact multiple systems in the body.

Professor Helena Teede, an endocrinologist at Monash Health and Director of Monash University’s Monash Centre for Health Research &amp. Implementation, led the name change process. Teede noted that current medical knowledge contradicts the previous naming convention.

According to Professor Teede, What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.

The shift in terminology is designed to steer clinical focus away from the ovaries alone and toward the systemic effects of the syndrome, which include impacts on weight, metabolic health, mental health, the skin, and the reproductive system.

A 14-Year Collaborative Process

The journey to rename the condition was a global collaboration that spanned 14 years. This effort involved the International PCOS Network and more than 50 professional and patient organizations, including the Endocrine Society.

The results of this collaboration were published on May 12, 2026, in the medical journal The Lancet. The process incorporated the expertise of medical professionals as well as the lived experiences of those affected by the syndrome.

Professor Teede highlighted the necessity of this change to improve patient outcomes, stating:

It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition. While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition.

Professor Helena Teede

Clinical Characteristics and Diagnosis

PMOS is recognized as the most common hormonal disorder among women of reproductive age. While the previous name focused on cysts, the condition is actually identified by a combination of hormonal and physical markers.

Diagnosis typically occurs when a woman presents at least two of the following three features:

• Irregular menstrual periods.
• High levels of testosterone or related physical symptoms, such as excess facial hair.
• An excess of antral ovarian follicles as seen on an ultrasound.

Medical advancements have also introduced alternative diagnostic methods. A blood test measuring high levels of anti-Müllerian hormone can now be used to replace the ultrasound in the diagnostic process.

Beyond the primary diagnostic criteria, women with PMOS may experience several other symptoms, including acne, heavy periods, difficulty getting pregnant, and patches of darker, velvety skin.

Long-Term Health Implications

The new name, Polyendocrine Metabolic Ovarian Syndrome, explicitly includes the term metabolic to highlight the systemic risks associated with the disorder. Because it is a long-term endocrine condition, it can lead to significant health complications if not managed properly.

Potential complications associated with PMOS include:

• Type 2 diabetes and obesity.
• Heart disease and obstructive sleep apnea.
• Mood disorders.
• Endometrial cancer.

While the exact cause of PMOS remains uncertain, research indicates a clear genetic component, with environmental factors also believed to contribute to the development of the syndrome.

Management of the condition typically involves a combination of healthy lifestyle adjustments and medication. Common pharmacological interventions include birth control pills, metformin, anti-androgens, and fertility treatments such as letrozole.